Here is a look at Alzheimer’s disease, a progressive brain disorder that leads to loss of memory and other intellectual abilities. Facts Alzheimer’s disease is the most common form of dementia, which ...

Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for slowing its progression. T ...

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based ... Eisai and Biogen's Leqembi (lecanemab) onto the US market ...

There had been speculation last year that Roche would move ahead with a quick filing for gantenerumab after Biogen got a controversial accelerated approval for Aduhelm (aducanumab) using amyloid ...

1 Despite the pressing social and economic imperative, new pharmacological treatments for dementia have been slow to develop with only one new drug (Aducanumab ... Recently, two new candidates, ...

New drugs for early Alzheimer’s disease may allow people to live without help for up to 39 additional months, a new study estimates. But experts urge caution.

M Health Fairview now offers both Alzheimer's infusion treatments — lecanemab and donanemab — both of which slow the ...

In the past two years, the Food and Drug Administration has approved two novel Alzheimer's therapies, based on data from ...

In the past two years, the Food and Drug Administration has approved two novel Alzheimer's therapies, based on data from clinical trials showing that both drugs slowed the progression of the disease.

Six new drugs, including a treatment for patients with advanced breast cancer, have been approved for use by the NHS in Scotland. The Scottish Medicines Consortium (SMC) has given the green light ...

Neurochemical dementia diagnostics (NDD) is a routine laboratory tool used in the diagnostic process for patients with neurodegenerative disorders, such as Alzheimer's disease. Currently, two ...